Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR Gross Margin
Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.
Lifecore Biomedical, Inc.NASDAQ: LFCR
Gross Margin · Q3 FY2026 · quarter ended Mar 2026
Gross margin at 19.2%
Gross margin was 19.2% in Q3 FY2026. On a trailing-twelve-month basis it was 31.2%. Over 3 fiscal years it narrowed by 3.8 pp.
Context
- Gross margin widened in 1 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 31.3%
- Year-over-year change
- -1.4pp
| Period | Period end | Gross Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-05-25 | 31.3% | -1.4pp |
| FY2024 | 2024-05-26 | 32.6% | +5.5pp |
| FY2023 | 2023-05-28 | 27.1% | -8.0pp |
| FY2022 | 2022-05-29 | 35.1% | -3.5pp |
| FY2021 | 2021-05-31 | 38.6% | — |
Gross Margin vs competitors
How LFCR compares with its peers on the latest reported figures
- LFCR's LTM Mar 2026 gross margin of 31.2% is the 7th highest of the 9 companies compared; the peer median is 71.1%.
- Over three fiscal years its change of -3.8 pp compares with a peer median of -1.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
BIOABioAge Labs, Inc. | LTM Mar 2026 | 99.4% | -0.6 pp | — |
| LTM Mar 2026 | 89.7% | -10.3 pp | -17.0 pp | |
| LTM Mar 2026 | 86.2% | +0.5 pp | +3.5 pp | |
| LTM Mar 2026 | 85.5% | +1.8 pp | +7.6 pp | |
| LTM Mar 2026 | 56.6% | +2.0 pp | -1.4 pp | |
| LTM Mar 2026 | 33.3% | +12.3 pp | -9.0 pp | |
| LTM Mar 2026 | 31.2% | — | -3.8 pp | |
| LTM Mar 2026 | 24.9% | -4.7 pp | +39.2 pp | |
| FY2025 | -1117.6% | -136.1 pp | -6.4 pp | |
| FY2025 | — | — | — | |
| Peer median (excluding LFCR) | 71.1% | -0.1 pp | -1.4 pp | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 May 2021 | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 |
|---|---|---|---|---|---|
| Revenue | 100.87M | 111.27M | 103.27M | 128.26M | 128.87M |
| Cost of Revenue | 61.94M | 72.2M | 75.28M | 86.41M | 88.57M |
| Gross Profit | 38.94M | 39.07M | 27.99M | 41.85M | 40.3M |
| Gross Margin | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% |
| Research & Development | 6.68M | 7.84M | 8.74M | 8.58M | 8.26M |
| Selling, General & Admin | 27.72M | 34.66M | 38.97M | 40.46M | 44.05M |
| Operating Expenses | 47.76M | 50.86M | 49.78M | 50.69M | 57.54M |
| Depreciation & Amortization | 19.87M | 18.06M | 13.18M | 8M | 8.03M |
| EBITDA | (987K) | 12.84M | (33.17M) | 35.6M | (8.81M) |
| EBITDA Margin | -1.0% | 11.5% | -32.1% | 27.8% | -6.8% |
| Operating Income | (8.82M) | (11.79M) | (21.8M) | (8.84M) | (17.25M) |
| Operating Margin | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% |
| Interest Income | 48K | 81K | 68K | 0 | 0 |
| Interest Expense | 8.93M | 15.55M | 17.65M | 18.09M | 21.84M |
| Other Income / Expenses | (20.96M) | (8.9M) | (42.13M) | 18.36M | (21.43M) |
| Income Before Tax | (29.79M) | (20.69M) | (63.93M) | 9.51M | (38.67M) |
| Pre-Tax Margin | -29.5% | -18.6% | -61.9% | 7.4% | -30.0% |
| Income Tax Expense | (6.35M) | (5.21M) | 308K | 183K | 43K |
| Net Income | (32.29M) | (116.72M) | (99.56M) | 12.01M | (38.72M) |
| Net Margin | -32.0% | -104.9% | -96.4% | 9.4% | -30.0% |
| EPS (Basic) | (1.12) | (3.97) | (3.32) | 0.39 | (1.27) |
| EPS (Diluted) | (1.12) | (3.97) | (3.32) | 0.33 | (1.27) |
| Weighted Avg Shares | 29.29M | 29.47M | 29.96M | 30.47M | 34.82M |
| Weighted Avg Shares (Diluted) | 29.29M | 29.47M | 29.96M | 36.66M | 34.82M |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.